Terms: = Germ cell tumor AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
20 results:
1. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression.
Chen X; Chen Y; Chen X; Wei P; Lin Y; Wu Z; Lin Z; Kang D; Ding C
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166534. PubMed ID: 36057370
[TBL] [Abstract] [Full Text] [Related]
3. Altered Frequencies and Functions of Innate Lymphoid cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Cristiani CM; Capone M; Garofalo C; Madonna G; Mallardo D; Tuffanelli M; Vanella V; Greco M; Foti DP; Viglietto G; Ascierto PA; Spits H; Carbone E
Front Immunol; 2022; 13():811131. PubMed ID: 35173725
[TBL] [Abstract] [Full Text] [Related]
4. Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/AKT signaling pathway.
Niu Z; Li Y; Xu Y; Jiang W; Tao R; Chen Y; Han Y
Bioengineered; 2021 Dec; 12(2):12193-12205. PubMed ID: 34783295
[TBL] [Abstract] [Full Text] [Related]
5. Targetable molecular alterations in congenital glioblastoma.
Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
[TBL] [Abstract] [Full Text] [Related]
6. MiR-154 inhibits cells proliferation and metastasis in melanoma by targeting AURKA and serves as a novel prognostic indicator.
Wang J; Fang Y; Liu YF; Wang X; Wang XL; Wang RY; Meng ZD
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4275-4284. PubMed ID: 31173299
[TBL] [Abstract] [Full Text] [Related]
7. Gynecologic melanomas: A clinicopathologic and molecular analysis.
Udager AM; Frisch NK; Hong LJ; Stasenko M; Johnston CM; Liu JR; Chan MP; Harms PW; Fullen DR; Orsini A; Thomas DG; Lowe L; Patel RM
Gynecol Oncol; 2017 Nov; 147(2):351-357. PubMed ID: 28844540
[TBL] [Abstract] [Full Text] [Related]
8. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract] [Full Text] [Related]
9. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract] [Full Text] [Related]
10. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
Yuan J; Zhou J; Dong Z; Tandon S; Kuk D; Panageas KS; Wong P; Wu X; Naidoo J; Page DB; Wolchok JD; Hodi FS
Cancer Immunol Res; 2014 Feb; 2(2):127-32. PubMed ID: 24778276
[TBL] [Abstract] [Full Text] [Related]
11. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract] [Full Text] [Related]
12. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract] [Full Text] [Related]
13. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.
Moreno L; Popov S; Jury A; Al Sarraj S; Jones C; Zacharoulis S
J Neurooncol; 2013 Jan; 111(2):169-76. PubMed ID: 23135775
[TBL] [Abstract] [Full Text] [Related]
14. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F
Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303
[TBL] [Abstract] [Full Text] [Related]
15. Recurrent seminomas: clinical features and biologic implications.
Som A; Zhu R; Guo CC; Efstathiou E; Xiao L; Pisters LL; Matin A; Tu SM
Urol Oncol; 2012; 30(4):494-501. PubMed ID: 20822932
[TBL] [Abstract] [Full Text] [Related]
16. Primary intradural chordoma: report on three cases and review of the literature.
Bergmann M; Abdalla Y; Neubauer U; Schildhaus HU; Probst-Cousin S
Clin Neuropathol; 2010; 29(3):169-76. PubMed ID: 20423692
[TBL] [Abstract] [Full Text] [Related]
17. The biology and management of uveal melanoma.
Sato T; Han F; Yamamoto A
Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273
[TBL] [Abstract] [Full Text] [Related]
18. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract] [Full Text] [Related]
19. Expression of kit and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract] [Full Text] [Related]
20. Role and regulation of the thrombin receptor (PAR-1) in human melanoma.
Tellez C; Bar-Eli M
Oncogene; 2003 May; 22(20):3130-7. PubMed ID: 12789289
[TBL] [Abstract] [Full Text] [Related]
